, LLC, announced today its execution of a purchase agreement to acquire the Discovery and Preclinical business of 

 with facilities in Bothell, Washington; Lyon, France; and Taipei, Taiwan.  Company headquarters will remain in Concord, Ohio.  
 
Ricerca Chairman and CEO Ian Lennox stated, “The addition of these facilities and personnel complement Ricerca’s existing facility in Concord, Ohio, and position us as a global, preferred provider of discovery and development services.  We have intimate working knowledge of these facilities; all are steeped in decades of experience and expertise.”
 
The proposed transaction between the two organizations is subject to customary regulatory and closing conditions.  The transaction is expected to close within the next two months.


Ricerca Biosciences currently has capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up and IND-enabling toxicology. The addition of the MDS Pharma Services molecular profiling, pharmacology/DMPK and drug safety assessment services will allow Ricerca to offer a more comprehensive suite of discovery and preclinical services to support drug candidates from discovery through IND on a global scale.
